Gilead is voluntarily recalling 2 lots of Veklury® (remdesivir) due to the presence of glass particulates.

Veklury is indicated for the treatment of COVID-19 in patients aged 12 years and older (weighing at least 40kg) requiring hospitalization. The lyophilized powder formulation is supplied in single dose clear glass vials and requires reconstitution at the site of use.

The recalled lots of Veklury (remdesivir 100mg for injection); NDC Number 61958-2901-02, were distributed nationwide in the United States and include the following:

  • Lot number: 2141001-1A; expiration date: 01/2024; distribution date to wholesalers: 10/25/21 to 10/26/21;
  • Lot number: 2141002-1A; expiration date: 01/2024; distribution date to wholesalers: 10/26/21 to 11/02/21.

To date, the Company has not received any reports of adverse events related to this recall. Consumers with any questions should contact Gilead Medical Information at (866) 633-4474.

Adverse events or quality issues should be reported to the Food and Drug Administration’s MedWatch Adverse Event Reporting program


Gilead issues a voluntary nationwide recall of two lots of Veklury® (remdesivir) due to presence of glass particulates. News release. Gilead Sciences Inc. December 3, 2021.